Viewing nowCombinationPimaropine Tablet 60/5 mg
Fimasartan Potassium Trihydrate 66.01mg · S-Amlodipine Besylate 2.5 Hydrate 7.48mg
Tablet · Prescription medication · Combination
Bionex Co., Ltd.

MFDS item code 202300099 · Approved 2023.01.06 · Insurance code 643105680
Treatment of essential hypertension not controlled with fimasartan monotherapy
Pimasartan potassium is used additionally when blood pressure is not sufficiently controlled with monotherapy in patients with essential hypertension, helping to adequately control blood pressure.
The recommended dose of this medicine is 1 tablet once daily, taken with water, with or without food. If possible, it is recommended to take it at the same time each day (e.g., in the morning). It is recommended that the dose be adjusted with fimasartan before administering this medicine. However, if blood pressure is not controlled as described below, switching directly to this medicine may be considered. ㆍ 30/2.5 milligrams: For patients whose blood pressure is not adequately controlled with fimasartan 30 milligrams alone. ㆍ 60/2.5 milligrams: For patients whose blood pressure is not adequately controlled with fimasartan 60 milligrams alone. ㆍ 60/5 milligrams: For patients whose blood pressure is not adequately controlled with fimasartan 60 milligrams alone or this medicine 60/2.5 milligrams. Patients taking fimasartan and S-amlodipine (amlodipine) concomitantly may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience. Elderly patients No initial dose adjustment is required for elderly patients aged 70 years or younger. Patients with renal impairment No dose adjustment is required in patients with mild to moderate renal impairment (creatinine clearance 30 ~ 80 mL/min). For patients with severe renal impairment (creatinine clearance < 30 mL/min), treatment should be initiated with fimasartan 30 milligrams in this medicine. Patients with hepatic impairment No dose adjustment is required in patients with mild hepatic impairment. This medicine should not be administered to patients with moderate to severe hepatic impairment.
The safety and efficacy of this medicine have not been established in children and adolescents aged 18 years or younger.
This medication can cause serious harm to the fetus and newborn when taken during pregnancy, especially in the second and third trimesters; therefore, discontinuation should occur immediately upon confirmation of pregnancy. Patients with allergies to the active ingredient or similar ingredients, pregnant or breastfeeding women, patients on kidney dialysis, patients with moderate to severe liver impairment, patients with biliary obstruction, diabetic patients with certain kidney diseases, patients who are lactose intolerant, patients with severe aortic stenosis, and patients in shock should not take this medication. Patients with low blood volume or sodium deficiency, patients with impaired kidney function, patients with renal artery hypertension, patients with aortic and mitral stenosis or obstructive heart diseases, patients with primary hyperaldosteronism, patients with severe hypotension, elderly patients, and patients allergic to specific pigment ingredients should be administered this medication with caution. While taking this medication, side effects such as dizziness, headache, facial swelling, urinary disturbances, insomnia, and flushing may occur, and in rare cases, serious neurological, gastrointestinal, cardiovascular, or hepatic disorders have been reported. There is a particular risk of hypotension, electrolyte imbalances, hyperkalemia, and acute renal failure, so immediate consultation with healthcare professionals is necessary if these symptoms arise. This medication may interact with other antihypertensives, diuretics, potassium-sparing diuretics, lithium, non-steroidal anti-inflammatory drugs, and so forth; therefore, it is essential to inform of any other medications being taken. Pregnant or breastfeeding women should consult healthcare professionals before taking this medication and are advised to avoid it while breastfeeding. Safety for use in children and adolescents under 18 years has not been established and is therefore not recommended. Elderly individuals may react more sensitively to this medication and should take precautions while using it. Patients with moderate to severe liver impairment should avoid taking this medication. In case of overdose, symptoms of hypotension, palpitations, and reflex tachycardia may occur; immediate medical treatment is required. This medication should be kept out of reach of children, and transferring it to another container is not advisable as it may adversely affect quality.
Not everyone experiences these, and they can vary from person to person.
This medication is sensitive to light and should be stored in a container that does not allow light to enter. It is also crucial to maintain a room temperature between 1 to 30 degrees Celsius for storage. This helps preserve the medication's efficacy.
Orange, rounded square film-coated tablets
30 tablets/bottle, 300 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationFimasartan Potassium Trihydrate 66.01mg · S-Amlodipine Besylate 2.5 Hydrate 7.48mg
Tablet · Prescription medication · Combination
Bionex Co., Ltd.
CombinationFimasartan Potassium Trihydrate 66.01mg · S-Amlodipine Besylate 2.5 Hydrate 7.48mg
Tablet · Prescription medication · Combination
Donggu Bio Pharmaceutical Co., Ltd.
CombinationFimasartan Potassium Trihydrate 33.005mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
Donggu Bio Pharmaceutical Co., Ltd.
CombinationFimasartan Potassium Trihydrate 66.01mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
Donggu Bio Pharmaceutical Co., Ltd.
CombinationFimasartan Potassium Trihydrate 33.005mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
NBK Pharmaceutical Co., Ltd.
CombinationFimasartan Potassium Trihydrate 33.005mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
Ajou Pharmaceuticals Co., Ltd.
CombinationFimasartan Potassium Trihydrate 33.005mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
Kips Biopharma Co., Ltd.
CombinationFimasartan Potassium Trihydrate 33.005mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
Bionex Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.